Journal of Antimicrobial Chemotherapy (2001) 47, 43-50
© 2001 The British Society for Antimicrobial Chemotherapy
Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study
a Department of Infectious Diseases, University Hospital of Umeå; b Department of Infectious Diseases, University Hospital of Lund; c Department of Infectious Diseases, Norrköping Hospital; d Department of Infectious Diseases, Danderyd Hospital; e Astra Läkemedel AB; f Department of Microbiology and Infectious Diseases, Karolinska Institute, Huddinge University Hospital, Sweden
The frequency of antibiotic-associated diarrhoea (AAD) and Clostridium difficile-associated diarrhoea (CdAD) was prospectively determined in a population of 2462 patients recruited from five Swedish hospitals, including divisions for infectious diseases, orthopaedics, surgery, geriatrics, nephrology and internal medicine. AAD developed in 4.9% of the treated patients. Faecal samples were obtained from 69% of patients with AAD and 55.4% were positive for C. difficile cytotoxin B. The frequency of AAD varied from 1.8 to 6.9% at the participating centres (P < 0.001). The frequency of AAD also varied considerably between medical disciplines and wards within different hospitals and was highest in the nephrology and geriatric units (6.7 and 7.1%, respectively). There was no difference in frequency of AAD when analysed with respect to gender or age. Medical interventions (laxative treatment, endoscopy and abdominal surgery) or presence of one concomitant disease (diabetes, malignancy, chronic renal disease and inflammatory bowel disease) did not significantly affect the frequency of AAD, whereas patients suffering from two or more of these illnesses had significantly (P = 0.001) higher frequencies of AAD. Patients treated with antibiotics for 3 days had a significantly (P = 0.009) lower frequency of AAD than those treated for longer periods. Treatment with cephalosporins, clindamycin or broad-spectrum penicillins was associated with an increased risk of AAD. With specimens from one centre, 62.5% of tested patients with AAD and 33.8% of asymptomatic patients were positive for cytotoxin B. Although C. difficile cytotoxin B in stool samples was significantly associated with AAD (P = 0.003), the causal relationship with diarrhoea is not always evident.
* Corresponding author. Tel: +46-90-7852305; Fax: +46-90-133006; E-mail: johan.wistrom.us{at}vll.se
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A C. Morris, K Kefala, A J Simpson, T S Wilkinson, K Everingham, D Kerslake, S Raby, I F Laurenson, D G Swann, and T S Walsh Evaluation of the effect of diagnostic methodology on the reported incidence of ventilator-associated pneumonia Thorax, June 1, 2009; 64(6): 516 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wallace Clinical Use of Probiotics in the Pediatric Population Nutr Clin Pract, February 1, 2009; 24(1): 50 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Saxton, S. D. Baines, J. Freeman, R. O'Connor, and M. H. Wilcox Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model Antimicrob. Agents Chemother., February 1, 2009; 53(2): 412 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Blondeau What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J. Antimicrob. Chemother., February 1, 2009; 63(2): 238 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Louie, M. Miller, C. Donskey, K. Mullane, and E. J. C. Goldstein Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection Antimicrob. Agents Chemother., January 1, 2009; 53(1): 223 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Karlowsky, N. M. Laing, and G. G. Zhanel In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile Antimicrob. Agents Chemother., November 1, 2008; 52(11): 4163 - 4165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Halsey Current and future treatment modalities for Clostridium difficile-associated disease Am. J. Health Syst. Pharm., April 15, 2008; 65(8): 705 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Shue, P. S. Sears, S. Shangle, R. B. Walsh, C. Lee, S. L. Gorbach, F. Okumu, and R. A. Preston Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1391 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Camacho, C. Espinoza, C. Rodriguez, and E. Rodriguez Isolates of Clostridium perfringens recovered from Costa Rican patients with antibiotic-associated diarrhoea are mostly enterotoxin-negative and susceptible to first-choice antimicrobials J. Med. Microbiol., March 1, 2008; 57(3): 343 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Adams, M. M. Riggs, and C. J. Donskey Effect of Fluoroquinolone Treatment on Growth of and Toxin Production by Epidemic and Nonepidemic Clostridium difficile Strains in the Cecal Contents of Mice Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2674 - 2678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Johnston, A. L. Supina, and S. Vohra Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. Can. Med. Assoc. J., August 15, 2006; 175(4): 377 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W Garey, G. Graham, L. Gerard, T. Dao, Z. D. Jiang, M. Price, and H. L DuPont Prevalence of Diarrhea at a University Hospital and Association with Modifiable Risk Factors Ann. Pharmacother., June 1, 2006; 40(6): 1030 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Aspevall, A. Lundberg, L. G. Burman, T. Akerlund, and B. Svenungsson Antimicrobial Susceptibility Pattern of Clostridium difficile and Its Relation to PCR Ribotypes in a Swedish University Hospital. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1890 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Musher, N. Logan, V. Mehendiratta, R. E. Polk, M. Oinonen, A. Pakyz, M. H. Wilcox, J. Freeman, K. Iwata, A. Doi, et al. Epidemic Clostridium difficile. N. Engl. J. Med., March 16, 2006; 354(11): 1199 - 1203. [Full Text] [PDF]
|
|
|
|
|
|
B. Lell, R. Ruangweerayut, J. Wiesner, M. A. Missinou, A. Schindler, T. Baranek, M. Hintz, D. Hutchinson, H. Jomaa, and P. G. Kremsner Fosmidomycin, a Novel Chemotherapeutic Agent for Malaria Antimicrob. Agents Chemother., February 1, 2003; 47(2): 735 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lell and P. G. Kremsner Clindamycin as an Antimalarial Drug: Review of Clinical Trials Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2315 - 2320. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Barbut and J. L. Meynard Managing antibiotic associated diarrhoea BMJ, June 8, 2002; 324(7350): 1345 - 1346. [Full Text] [PDF]
|
|
|
|
|
|
J. G. Bartlett Antibiotic-Associated Diarrhea N. Engl. J. Med., January 31, 2002; 346(5): 334 - 339. [Full Text] [PDF]
|
|
|
|
|
|
J. Freeman and M. H. Wilcox Ureidopenicillins and risk of Clostridium difficile infection J. Antimicrob. Chemother., May 1, 2001; 47(5): 719 - 719. [Full Text] [PDF]
|
|